INTRA-CELLULAR THERAPIES INC (ITCI) Stock News
NASDAQ:ITCI - Nasdaq - US46116X1019 - Common Stock - Currency: USD
ITCI Latest News, Press Relases and Analysis
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITCI, PWOD, EBTC on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK and ITCI on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: SSTK
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive
Mentions: JNJ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: ENFN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
The deal values the smaller biotech company at a 39% premium to last week's closing price.
Mentions: JNJ
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.
Mentions: JNJ